Подходы к разработке наносомальной лекарственной формы рифампицина
Диссертация
Известно, что распределение лекарств в организме можно целенаправленно менять как на клеточном, так и на тканевом уровне, используя различные системы доставки. В последние годы отмечается возрастающий интерес к коллоидным системам доставки лекарственных веществ (JIB): липосомам, микрочастицам, наночастицам. Идея внутривенного использования таких систем для повышения избирательности действия… Читать ещё >
Список литературы
- Рифампицин кристаллический порошок НД 42−9301−98
- Рифампицин Ферейн®-, лиофилизат для приготовления раствора для инъекций 0,15 г. ФСП 420 053 171 901
- Рифампицин 0,05 г и 0,15 г в капсулах. ФС 42−2058−97
- Adams LB, Sinha I, Franzblau SG, Krahenbuhl JL, Mehta RT. Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. Antimicrob Agents Chemother. 1999 Jul-43(7): 1638−43
- Ahsan F, Rivas IP, Khan MA, Torres Suarez Al. Targeting to macrophages: role of physicochemical properties of particulate carriers—liposomes and microspheres~on the phagocytosis by macrophages. J Control Release. 2002 Feb 19−79(l-3):29−40. Review.
- Ain Q., Sharma S, Khuller GK, Garg SK. Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. J Antimicrob Chemother. 2003 Apr-51(4):931−8. Epub 2003 Mar 13.
- Ain Q., Sharma S., Garg S.D., Khuller G.D. Role of poly (DL-lactide-co-glycolide) in development of a sustained oral delivery system for antitubercular drug (s). International Journal of Pharmaceutics 239 (2002) 37−46
- Araujo L., Lobenberg R., Kreuter J. Influence of the surfactant concentration on the body distribution of nanoparticlesJ Drug Targeting 6 (1999) 373 385
- Arias JL, Gallardo V, Gomez-Lopera SA, Plaza RC, Delgado AV. Synthesis and characterization of poly (ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. J Control Release. 2001 Dec 13−77(3):309−21.
- Bain DF, Munday DL, Cox PJ Evaluation of biodegradable rifampicin-bearing microsphere formulations using a stability-indicating high-performance liquid chromatographic assay: Eur J Pharm Sci. 1998 Dec-7(l):57−65
- Barrow EL, Winchester GA, Staas JK, Quenelle DC, Barrow WW. Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob Agents Chemother. 1998 Oct- 42(10):2682−9.
- Beaulac C, Sachetelli S, Lagace J. Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa. J Drug Targeting 1999- 7: 33−41.
- Behan N, Birkinshaw C, Clarke N. Poly n-butyl cyanoacrylate nanoparticles: a mechanistic study of polymerisation and particle formation Biomate-rials. 2001 Jun- 22(11):1335−44.
- Brigger I, Chaminade P, Desmaele D, Peracchia MT, d’Angelo J, Gurny R, Renoir M, Couvreur P. Near infrared with principal component analysis as a novel analytical approach for nanoparticle technology. Pharm Res. 2000 Sep- 17(9): 1124−32.
- Brigger I, Morizet J, Aubert G, Chacun H, Terrier-Lacombe MJ, Couvreur P, Vassal G. Poly (ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J Pharmacol Exp Ther. 2002 Dec- 303 (3):928−36.
- Calvo P, Gouritin B, Chacun H, Desmaele D, D’Angelo J, Noel JP, Geor-gin D, Fattal E, Andreux JP, Couvreur P. Long-circulating PEGylated poly-cyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res. 2001 Aug- 18 (8):1157−66.
- Conley J, Yang H, Wilson T, et al. Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Fran-cisella tularenis infection in mice. Antimicrobial Agents Chemother 1997- 41: 1288−1292.
- Demoy M., Andreux J.-P., Weingarten C., Gouritin В., Guilloux V., Couvreur P. Spleen Capture of Nanoparticles: Influence of Animal Species and Surface Characteristics. Pharmaceutical Research, vol. 16 No. 1. 1999
- Deol P, Khuller GK Lung specific stealth liposomes: stability, biodistribu-tion and toxicity of liposomal antitubercular drugs in mice Biochim Biophys Acta. 1997 Mar 15- 1334 (2−3):161−72
- Deol P, Khuller GK, Joshi K. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacteriumtuberculosis infection induced in mice. Antimicrob Agents Chemother. 1997 Jun- 41 (6): 12.11−4
- Dhillon J, Fielding R, Adler-Moore J, Goodall RL, Mitchison D. The activity of low-clearance liposomal amikacin in experimental murine tuberculosis. J Antimicrob Chemother. 2001 Dec-48(6):869−76.
- Donald PR, Sirgel FA, Venter A, Smit E, Parkin DP, Van de Wal BW, Mitchison DA The early bactericidal activity of a low-clearance liposomal amikacin in pulmonary tuberculosis J Antimicrob Chemother. 2001 Dec-48(6):877−80
- Douglas S.J., Ilium L., and Davis S.S. Particle size and size distribution fo poly (butyl 2-cyanoacrylate) nanoparticles. II. Influence of stabilizers. Journal of Colliid and Interface Science. Vol. 103 No. 1 January 1985.
- Douglas S.J., Ilium L., Davis S.S., and Kreuter J. Particle size and size distribution of poly (butyl-2-cyanoacrylate) nanoparticles I. Influence of physico-chemical Factors. Journal of Colloid and Interface Science. Vol. 101, No. 1, September 1984
- Duchene D, Ponchel G, Wouessidjewe D. Cyclodextrins in targeting. Application to nanoparticles. Adv Drug Deliv Rev. 1999 Mar l-36(l):29−40.
- Dutt M, Khuller GK Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles J Antimicrob Chemother. 2001 Jun-47(6):829−35
- Dutt M, Khuller GK. Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int J Antimicrob Agents. 2001 Feb- 17(2): 115−22.
- Dutt M, Khuller GK. Therapeutic efficacy of Poly (DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother. 2001 Jan-45(l):363−6.
- Elder AC, Gelein R, Oberdorster G, Finkelstein J, Notter R, Wang Z. Efficient depletion of alveolar macrophages using intratracheally inhaled aerosols of liposome-encapsulated clodronate. Exp Lung Res. 2004 Mar- 30 (2): 105−20.
- Emary WB, Toren PC, Mathews B, Huh K. Disposition and metabolism of rifapentine, a rifamycin antibiotic, in mice, rats, and monkeys. Drug Metab Dispos. 1998 Aug-26(8):725−31.
- Fattal E, Youssef M, Couvreur P, Andremont A. Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles. Antimicrob Agents Chemother 1989- 33: 1540−3
- Fawaz F., Bonini F., Maugein J., Lagueny A.M. Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: pharmacokinetics and in vitro antimicrobial activity. International Journal of Pharmaceutics 168 (1998) 255−259
- Fawaz F., Guyot M., Lagueny A.M., Devissaguet J.Ph. Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: preparation and characterization. International Journal of Pharmaceutics 154 (1997) 197−203
- Gaspar MM, Neves S, Portaels F, Pedrosa J, Silva MT, Cruz ME. Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection. Antimicrob Agents Chemother. 2000 Sep-44(9):2424−30.
- Gipps E., Groscurt P., Kreuter J., Speiser P.P. The effects of poly (alkylcyanoaciylate) nanoparticles on human normal and malignant nesen-chymal cells in vitro. Int. J. Pharm. 40 (1987) 23−31
- Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res. 1999 Oct-16 (10):1564−9
- Henry-Michelland S, Alonso MJ, Andremont A, Maincent P, Sauzieres J, Couvreur P. Attachment of antibiotics to nanoparticles: preparation, drug release and antimicrobial activity in vitro. Int J Pharm 1987- 35: 121−7
- Ilium L., Khan M.A., Мак E., and Davis S.S. Evaluation of carrier capacity and releaxe characteristics for poIy (butyl 2-cyanoacryIate) nanoparticles. International Journal of Pharmaceutics 30 (1986) 17−28.
- Kabanov A.V., Lemieux P., Vinogradov S., Alakhov V. Pluronic® block copolymers: novel functional molecules for gene therapy. Advanced Drug Delivery Reviews 54 (2002) 223−233
- Kabanov AV, Batrakova EV, Miller DW. Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv Drug Deliv Rev. 2003 Jan 21−55(l):151−64. Review.
- Kante В., Couverur В., Dubois-Krack G., De Meester C., Guiot P., Roland M., Vercier M., Speiser P. (1982). Toxicity of polyalkylcyanoacrylate nanoparticles. I. Free nanoparticles. J. Pharm. Sci. 71: 786
- Kreuter J. Colliodal drug delivery systems. N.Y.: Marcel Dekker Inc, 1994.-352p
- Labana S, Pandey R, Sharma S, Khuller GK. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes Int J Antimicrob Agents. 2002 C) ct-20(4):301−4.
- Leemans JC, Juffermans NP, Florquin S, van Rooijen N, Vervoordeldonk MJ, Verbon A, van Deventer SJ, van der Poll T. Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice. J Immunol. 2001 Apr 1- 166(7): 4604−11.
- Lenaerts V., Nagelkerke J.F., van Berkel N.J.C., Couvreur P., Grislain L., Roland M., and Speiser P. (1984). Toxicity and association of polycyanoacry-late nanoparticles with hepatocytes. J. Microencapsul. 1: 253
- Lenaerts V., Raymond P., Juhasz J., Simard V.A., and Jolicoeur C. New method for the preparation of cyanoacrylic nanoparticles with improved colloidal properties. Journal of Pharmaceutical Sciences Vol. 78, No. 12, December 1989.
- Lherm C., Muller R., Puisieux F., Couvreur P. PP. Cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length. Int. J. Pharm. 84 (1992) 13−22
- Li YP, Pei YY, Zhou ZH, Zhang XY, Gu ZH, Ding J, Zhou JJ, Gao XJ, Zhu JH. Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers: pharmacokinetics and anti-tumor effects. Biol Pharm Bull. 2001 Jun- 24 (6): 662−5.
- Magenheim В., Benita S. Nanoparticle characterization: a comprehensive physicochemical approach. S.T.P. Pharma Sciences 1 (4) 221−241 1991.
- Miyazaki, Т., Kohno, S., Sasayama, K., Inoue, Y., Нага, K., Ogasawara, M., Sato, Т., and Sunamoto, J., Polysaccharide-anchored liposomal amphotericin В for the treatment of murine pulmonary candidiasis. Tohoku J Exp Med, 168:483−490, 1992
- Moghimi S.M. Re-establishing the long circulatory behaviour of poloxam-ine-coated particles after repeated intravenous administration: applications in cancer drug delivery and imaging. Biochimica et Biophysica Acta 1472 (1999) 399−403
- Moghimi S.M., Hunter A.C. Poloxamers and poloxamines in nanoparticles engineering and experimental medicine. Trends in Biotechnology, 18 (2000), 412−420
- Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001- 53: 283−318
- Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003 Nov- 42 (6):463−78. Review.
- Moghimi SM. Opsono-recognition of liposomes by tissue macrophages. International Journal of Pharmaceutics 162 (1998) 11 18.
- Muller R.H., Lherm C., Herbort J., Couvreur P. Propidium-iodide-loaded polyaldylcyanoacrylate particles — labeling conditions and ooading capacity. Colloid Polym Sci 269: 147−152 (1991).
- O’Hara P, Hickey AJ. Respirable PLGA microspheres containing rifam-picin for the treatment of tuberculosis: manufacture and characterization. Pharm Res. 2000 Aug-17(8):955−61.
- Page-Clisson M.-E., Pinto-Alphandary H., Ourevitch M., Andremont A., Couvreur P. Develppment of ciprofloxacin-loaded nanoparticles: physico-chemical study of the drug carrier. Journal of Controlled Release 56 (1998) 2332.
- Pandey R, Zahoor A, Sharma S, Khuller GK Nanoparticle encapsulated an-titubercular drugs as a potential oral drug delivery system against murine tuberculosis Tuberculosis (Edinb). 2003−83(6):373−8
- Pinto-Alphandary H, Andremont A, Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int J Antimicrob Agents. 2000 Jan- 13(3): 155−68. Review.
- Poiani, G.J., Kemnitzer, J.E., Fox, J.D., Tozzi, C.A., Kohn, J., Riley, and D J., Polymeric carrier of proline analogue with antifibrotic effect in pulmonary vascular remodelling. Am J Respair Crit Care Med, 155: 1384−1390, 1997
- Quenelle DC, Staas JK, Winchester GA, Barrow EL, Barrow WW. Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice. Antimicrob Agents Chemother. 1999 May-43(5):l 144−51.
- Quenelle DC, Winchester GA, Staas JK, Barrow EL, Barrow WW. Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid. Antimicrob Agents Chemother. 2001 Jun-45(6): 1637−44.
- Seijo В., Fattal E., Roblot-Treupel L., Couvreur P. Design of nanoparticles of less than 50 nm diameter: preparation, characterization and drug loading. International Journal of Pharmaceutics, 62 (1990) 1−7
- Sethuraman VV, Hickey AJ. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. AAPS PharmSciTech. 2002−3(4):E28.
- Sham JO, Zhang Y, Finlay WH, Roa WH, Lobenberg R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm. 2004 Jan 28−269(2):457−67.
- Sharma R., Saxena D., Dwivedi A.D., and Misra A. Inhalable Microparti-cles Containing Drug Combinations to Target Alveolar Macrophages for Treatment of Pulmonary Tuberculosis. Pharmaceutical Research, Vol. 18, No 10, October 2001
- Shishoo CJ, Shah SA, Rathod IS, Savale SS, Kotecha JS, Shah PB. Stability of rifampicin in dissolution medium in presence of isoniazid Int J Pharm. 1999 Nov 10- 190(1): 109−23
- Sihorkar V, Vyas SP Potential of polysaccharide anchored liposomes in drug delivery, targeting and immunization J Pharm Pharmaceut Sci (www.ualberta.ca/~csps) 4(2): 138−158, 2001
- Skidan IN, Bobruskin Al, Guliaev AE, Shalkharbaeva SD, Severin SE, Steinniger S, Kreuter J, Gel’perina SE. Optimization of «Photosens» pharma-kokinetics by biodegradable nanospheres Antibiot Khimioter. 2001−46(4):6−10
- Skidan IN, Gel’perina SE, Severin SE, Guliaev AE Enhanced activity of rifampicin loaded with polybutyl cyanoacrylate nanoparticles in relation to in-tracellularly localized bacteria Antibiot Khimioter. 2003−48(l):23−6
- Sommerfeld P., Schroeder U., Sabel B.A. Long-term stability of PBCA nanoparticles suspensions suggests clinical usefulness. International Journal of Pharmaceutics 155 (1997) 201−207
- Sommerfeld P., Schroeder U., Sabel B.A. Sterilization of unloaded polybu-tylcyanoacrylate nanoparticles. International Journal of Pharmaceutics 164 (1998) 113−118
- Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin Al, Smir-nova ZS, Severin SE, Uhl R, Коек M, Geiger KD, Gelperina SE. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer. 2004 May l-109(5):759−67-
- Suarez S, O’Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, Hickey AJ. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother. 2001 Sep-48(3):431−4.
- Sunamoto J., and Sato T. Improved drug delivery directed to specific tissue using polysaccharide-anchored liposomes, in Tsuruta, T: Nakajima, A (eds), Multiphase Biomedical Materials. The Netherlands, pp. 169−171, 1989
- Takada M., Yuzuriha Т., Katayama K., Iwamoto K., and Sunamoto J. Increased lung uptake of liposomes anchored with polysaccharides. Biochim Bio-phys Acta, 802: 237−244, 1984
- Torchilin V.P. Drug targeting. European Journal of Pharmaceutical Sciences 11 Suppl. 2 (2000) S81 S91
- Tseng Y.C., Hyon S.H., Ikada Y. Modification of the synthesis and investigation of properties for 2-cyanoacrylates, Biomaterials 11 (1990) 73−79
- Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P. Poly (alkylcyanoacrylates) as biodegradable materials for biomedical applications: Adv Drug Deliv Rev. 2003 Apr 25−55(4):519−48
- Vauthier C., Schmidt C., Couvreur P. Measurement of the density of polymeric nanoparticulate drug carriers by isopycnic centrifugation. Journal of Nanoparticle Research 1: 411−418, 1999
- Verdun C, Brasseur F, Vranckx H, Couvreur P, Roland M. Tissue distribution of doxorubicin associated with polyisohexylcyanoaciylate nanoparticles. Cancer Chemother Pharmacol. 1990−26(l):13−8.
- Vinogradov Serguei V., Bronich Tatiana K., Kabanov Alexander V. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Advanced Drug Delivery Reviews- 54 (2002) 135−147
- Vyas SP, Kannan ME, Jain S, Mishra V, Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm. 2004 Jan 9−269(l):37−49.
- Watnasirichaikul S, Rades T, Tucker IG, Davies NM. Effects of formulation variables on characteristics of poly (ethylcyanoacrylate) nanocapsules prepared from w/o microemulsions. Int J Pharm. 2002 Mar 20−235(l-2):237−46.
- Whitehead TC, Lovering AM, Cropley IM, Wade P, Davidson RN. Kinetics and toxicity of liposomal and conventional amikacin in a patient with mul-tidrug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis. 1998 Nov- 17(11):794−7
- Zhang Q, Liao GT, Wei DP, Zhang CJ. Increase of gentamicin uptake in cultured mouse peritoneal macrophage and rat hepatocytes when used in the form of nanoparticles. International Journal of Pharmaceutics 164 (1998) 21 -27.